Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth
Abstract Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials as a promising therapeutic modality....
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Nature Portfolio
2023-05-01
|
| Серія: | Scientific Reports |
| Онлайн доступ: | https://doi.org/10.1038/s41598-023-34965-4 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|